Pediatric eosinophilic esophagitis treatment with biologic therapy for children with rare disease
RegulatoryBusiness Wire

Regeneron and Sanofi Announce FDA Approval of Dupixent for Eosinophilic Esophagitis in Children

Regeneron and Sanofi receive FDA approval for Dupixent (dupilumab) for eosinophilic esophagitis in children aged 1-11 years, expanding treatment options for this rare condition.

Regeneron and Sanofi today announced that the FDA has approved Dupixent (dupilumab) for the treatment of eosinophilic esophagitis (EoE) in children aged 1 to 11 years weighing at least 15 kg. This approval makes Dupixent the first biologic approved for EoE in this age group. EoE is a chronic, allergic inflammatory disease of the esophagus that can cause difficulty swallowing, food impaction, and failure to thrive in children. In the Phase 3 EoE KIDS trial, Dupixent demonstrated significant improvements in histologic response and symptom scores compared to placebo. This approval expands Dupixent's use in pediatric patients with type 2 inflammatory diseases.

Original Source

Business Wire
Share:

Previous

Pfizer Receives FDA Approval for Elranatamab in Relapsed or Refractory Multiple Myeloma

Next

Johnson & Johnson Receives FDA Approval for Talvey in Relapsed or Refractory Multiple Myeloma